Acute Myeloid Leukemia in the Setting of Low Dose Weekly Methotrexate Therapy for Rheumatoid Arthritis

References

• Pincus T., O'Dell J. R., Kremer J M. Combination therapy with multiple disease-modifying antirheumatic drugs in rheumatoid arthritis: a preventive strategy. Annals of Internal Medicine 1999; 131: 768–774
   PubMed Web of Science ®Google Scholar
• Nyfors A., Jensen H. Frequency of malignant neoplasms in 248 long-term methotrexate-treated psoriatics. A preliminary study. Dermatologica 1983; 167: 260–261
   PubMedGoogle Scholar
• Bailin P. L., Tindall J. P., Roenigk H. H. Is methotrexate therapy for psoriasis carcinogenic? A modified retrospective-prospective analysis. Journal of the American Medical Association 1975; 232: 359–362
   PubMed Web of Science ®Google Scholar
• Arnett E. C., Edworthy S. M., Bloch D. A., McShane D. J., Fries J. F., Cooper N. S., Healey L. A., Kaplan S. R., Liang M. H., Luthra H. S., Medsger T. A., Jr, Mitchell D. M., Neustadt D. H., Finals R. S., Schaller J. G., Sharp J. T., Wilder R. L., Hunder O G. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis and Rheumatism 1988; 31: 315–24
   PubMed Web of Science ®Google Scholar
• Bennett J. M., Catovsky D., Daniel M. T., Flandrin G., Galton D. A., Gralnick H. R., Sultan C. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. Annals of Internal Medicine 1985; 103: 620–625
   PubMed Web of Science ®Google Scholar
• Bennett J. M., Catovsky D., Daniel M. T., Flandrin G., Galton D. A., Gralnick H. R., Sultan C. Proposal for the recognition of minimally differentiated acute myeloid leukaemia (AML-MO). British Journal of Haematology 1991; 78: 325–329
   PubMed Web of Science ®Google Scholar
• ISCN. An International System for Human Cytogenetic Nomenclature, F. Mitelman. Karger, Basel 1995
   Google Scholar
• Baer M. R., Stewart C. C., Lawrence D., Arthur D. C., Byrd J. C., Davey F. R., Schiffer C. A., Bloomfield C D. Expression of the neural cell adhesion molecule CD56 is associated with short remission duration and survival in acute myeloid leukemia with t(8;21)(q22;q22). Blood 1997; 90: 1643–1648
   PubMed Web of Science ®Google Scholar
• Baer M. R., Sjewart C. C., Lawrence D., Arthur D. C., Mrozek K., Strout M. P., Davey F. R., Schiffer C. A., Bloomfield C D. Acute myeloid leukemia with 11q23 translocations: myelomonocytic immunophenotype by multiparameter flow cytometry. Leukemia 1998; 12: 317–325
   PubMed Web of Science ®Google Scholar
• Den Boer M. L., Zwaan C. M., Pieters R., Kazemier K. M., Rottier M M, Flens M. J., Scheper R. J., Veerman A J. Optimal immunocytochemical and flow cytometric detection of P-gp, MRP and LRP in childhood acute lymphoblastic leukemia. Leukemia 1997; 11: 1078–1085
   PubMed Web of Science ®Google Scholar
• Young I T. Proof without prejudice: use of the Kolmogorov-Smirnov test for the analysis of histograms from flow systems and other sources. Journal of Histochemistry and Cytochemistry 1977; 25: 935–941
   PubMed Web of Science ®Google Scholar
• Boesch D., Muller K., Pourtier-Manzanedo A., Loor F. Restoration of daunomycin retention in multidrug-resistant P388 cells by submicromolar concentrations of SDZ PSC 833, a nonimmunosuppressive cyclosporin derivative. Experimental Cell Research 1991; 196: 26–32
   PubMed Web of Science ®Google Scholar
• Dalton W. S., Durie B. G., Alberts D. S., Gerlach J. H., Cress A E. Characterization of a new drug-resistant human myeloma cell line that expresses P-glycoprotein. Cancer Research 1986; 46: 5125–5130
   PubMed Web of Science ®Google Scholar
• Slovak M. L., Hoeltge G. A., Dalton W. S., Trent J M. Pharmacological and biological evidence for differing mechanisms of doxorubicin resistance in two human tumor cell lines. Cancer Research 1988; 48: 2793–2797
   PubMed Web of Science ®Google Scholar
• Marsh W., Sicheri D., Center M S. Isolation and characterization of adriamycin-resistant HL-60 cells which are not defective in the initial intracellular accumulation of drug. Cancer Research 1986; 46: 4053–4057
   PubMed Web of Science ®Google Scholar
• Baer M. R., George S. L., Dodge R. K., Cooke K., Caligiuri M. A., Powell B., Kolitz J. E., Larson R A. Phase HI study of PSC-833 modulation of multidrug resistance (mdr) in previously untreated acute myeloid leukemia patients 60 years (CALGB 9720). Blood 1999; 94: 383a
   Web of Science ®Google Scholar
• Baer M. R., Christiansen N. P., Frankel S. R., Brunetto V. L., Mrozek K., Bloomfield C. D., Herzig G P. High-dose cytarabine, idarubicin, and granulocyte colony-stimulating factor remission induction therapy for previously untreated de novo and secondary adult acute myeloid leukemia. Seminars in Oncology 1993; 20(Suppl 8)6–12
   PubMed Web of Science ®Google Scholar
• Cheson B. D., Cassileth P. A., Head D. R., Schiffer C. A., Bennett J. M., Bloomfield C. D., Brunning R., Gale R. P., Grever M. R., Keating M. J., Sawitsky A., Stass S., Weinstein H., Woods W. Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. Journal of Clinical Oncology 1990; 8: 813–819
   PubMed Web of Science ®Google Scholar
• Pointud P., Prudat M., Peron J. Acute leukemia after low dose methotrexate therapy in a patient with rheumatoid arthritis. Journal of Rheumatoloy 1993; 20: 1215–1216
   PubMed Web of Science ®Google Scholar
• Rosenthal N., Farhi D. Myelodysplastic syndromes and acute myeloid leukemia in connective tissue disease after single-agent chemotherapy. American Journal of Clinical Pathology 1996; 106: 676–679
   PubMed Web of Science ®Google Scholar
• Dubin Kerr L., Troy K., Isola L. Temporal association between the use of methotrexate and development of leukemia in 2 patients with rheumatoid arthritis. Journal of Rheumatology 1995; 22: 2356–2358
   PubMed Web of Science ®Google Scholar
• Moder K., Tefferi A., Cohen M., Menke D., Luthra H. Hematologic malignancies and the use of methotrexate in rheumatoid arthritis: a retrospective study. American Journal of Medicine 1995; 99: 276–281
   PubMed Web of Science ®Google Scholar
• Sheibani K., Bukowski R. M., Tubbs R. R., Savage R. A., Sebek B. A., Hoffman G C. Acute nonlym-phocytic leukemia in patients receiving chemotherapy for nonmalignant diseases. Human Pathology 1980; 11: 175–179
   PubMed Web of Science ®Google Scholar
• Grunwald H. W., Rosner F. Acute leukemia and inununosuppressive drug use: a review of patients undergoing immunosuppressive therapy for non-neoplastic diseases. Archives of Internal Medicine 1979; 139: 461–466
   PubMed Web of Science ®Google Scholar
• Karp J. E., Smith M A. The molecular pathogenesis of treatment-induced (secondary) leukenüas: foundations for treatment and prevention. Seminars in Oncology 1997; 24: 103–113
   PubMed Web of Science ®Google Scholar
• Arnold J. A., Ranson S. A., Abdalla S H. Azathioprine-associated acute myeloid leukaemia with trilineage dysplasia and complex karyotype: a case report and review of the literature. Clin Lab Haematology 1999; 21: 289–92
   PubMedGoogle Scholar
• Baer M. R., Bloomfield C D. Trisomy 13 in acute leukemia. Leukemia and Lymphoma 1992; 7: 1–6
   PubMed Web of Science ®Google Scholar
• Georgescu L., Quinn G., Schwartzman S., Paget S. Lymphoma in patients with rheumatoid arthritis: Association with the disease state or methotrexate treatment. Seminars in Arthritis and Rheumatism 1997; 26: 794–804
   PubMed Web of Science ®Google Scholar
• Isomäki H., Hakulinen T., Joutsenlahti U. Excess risk of lymphomas, leukemia and myeloma in patients with rheumatoid arthritis. Journal of Chronic Disease 1978; 31: 691–696
   PubMedGoogle Scholar
• Kinlen L J. Incidence of cancer in rheumatoid arthritis and other disorders after immunosuppressive treatment. American Journal of Medicine 1985; 78: 44–49
   PubMed Web of Science ®Google Scholar
• Symmons D P. Neoplasms of the immune system in rheumatoid arthritis. American Journal of Medicine 1985; 78: 22–28
   PubMed Web of Science ®Google Scholar
• Gridley G., McLaughlin J. K., Ekbom A., Klareskog L., Adami H. O., Hacker D. G., Hoover R., Fraumeni J. E. Incidence of cancer among patients with rheumatoid arthritis. Journal of the National Cancer Institute 1993; 85: 307–311
   PubMed Web of Science ®Google Scholar
• Radis C. D., Kahl L. E., Baker G. L., Wasko M. C., Cash J. M., Gallatin A., Stolzer B. L., Agarwal A. K., Medsger T. A., Kwoh C K. Effects of cyclophosphamide on the development of malignancy and on long-term survival of patients with rheumatoid arthritis. A 20-year followup study. Arthritis and Rheumatism 1995; 38: 1120–1127
   PubMed Web of Science ®Google Scholar
• Kanik K. S., Cash J M. Does methotrexate increase the risk of infection or malignancy. Rheumatic Disease Clinics of North America 1997; 23: 955–967
   PubMed Web of Science ®Google Scholar
• Jensen M. K., Nyfors A. Cytogenetic effects of methotrexate on human cells in vivo: comparison between results obtained by chromosome studies on bone-marrow cells and blood lymphocytes and by the micronucleus test. Mutation Research 1979; 64: 339–343
   PubMed Web of Science ®Google Scholar
• Ryan T. J., Boddington M. M., Spriggs A I. Chromosomal abnormalities produced by folk acid antagonists. British Journal of Dermatology 1965; 77: 541–555
   PubMed Web of Science ®Google Scholar
• Weinblatt M. E., Weissman B. N., Holdsworth D. E., Fraser P. A., Maier A. L., Falchuk K. R., Coblyn J S. Long-term prospective study of methotrexate in the treatment of rheumatoid arthritis. 84-month update. Arthritis and Rheumatism 1992; 35: 129–37
   PubMed Web of Science ®Google Scholar
• Weinstein A., Marlowe S., Kom J., Farouhar F. Low-dose methotrexate treatment of rheumatoid arthritis. Long-term observations. American Journal of Medicine 1985; 79: 331–337
   PubMed Web of Science ®Google Scholar
• Kremer J. M., Phelps C T. Lang-term prospective study of the use of methotrexate in the treatment of rheumatoid arthritis. Update after a mean of 90 months. Arthritis and Rheumatism 1992; 35: 138–145
   PubMed Web of Science ®Google Scholar
• Furst D. E., Erikson N., Clute L., Koehnke R., Burmeister L. F., Kohler J A. Adverse experience with methotrexate during 176 weeks of a longterm prospective trial in patients with rheumatoid arthritis. Journal of Rheumatology 1990; 17: 1628–1635
   PubMed Web of Science ®Google Scholar
• McKendry R., Cyr M. Toxicity of methotrexate compared with azathioprine in the treatment of rheumatoid arthritis. A case-control study of 131 patients. Archives of Internal Medicine 1989; 149: 685–689
   PubMed Web of Science ®Google Scholar
• Hazleman B. Incidence of neoplasms in patients with rheumatoid arthritis exposed to different treatment regimens. American Journal of Medicine 1985; 78(suppl 1A)39–43
   PubMed Web of Science ®Google Scholar
• Stern R. S., Zierler S., Parrish J A. Methotrexate used for psoriasis and the risk of noncutaneous or cutaneous malignancy. Cancer 1982; 50: 869–872
   PubMed Web of Science ®Google Scholar
• Rustin G., Rustin F., Dent J., Booth M., Salt S., Bagshawe K. No increase in second tumors after cytotoxic chemotherapy for gestational trophoblastic tumors. New England Journal of Medicine 1983; 308: 473–476
   PubMed Web of Science ®Google Scholar
• Jones M., Symmons D., Finn J., Wolfe F. Does exposure to immunosuppressive therapy increase the 10 year malignancy and mortality risks in rheumatoid arthritis? A matched cohort study. British Journal of Rheumatology 1996; 35: 738–745
   PubMedGoogle Scholar
• Williams C. A., Bloch D. A., Sibley J., Hags M., Wolfe F., Raynauld J. P., Singh G., Ffickey A. R., Fries J F. Lymphoma and leukemia in rheumatoid arthritis: a matched case-control study in the ARAMIS (Arthritis, Rheumatism and Aging Medical Information System) population. Arthritis and Rheumatism 1995; 38: S204
   Google Scholar